These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 34026622)

  • 1. Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
    Sun W; Zhang Q; Wang R; Li Y; Sun Y; Yang L
    Front Oncol; 2021; 11():648687. PubMed ID: 34026622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
    Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
    J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting ATR in cancer medicine.
    Sundar R; Brown J; Ingles Russo A; Yap TA
    Curr Probl Cancer; 2017; 41(4):302-315. PubMed ID: 28662958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting DNA Damage Response in Prostate and Breast Cancer.
    Wengner AM; Scholz A; Haendler B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer.
    Deng S; Vlatkovic T; Li M; Zhan T; Veldwijk MR; Herskind C
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic vulnerabilities upon inhibition of DNA damage response.
    Wang C; Tang M; Chen Z; Nie L; Li S; Xiong Y; Szymonowicz KA; Park JM; Zhang H; Feng X; Huang M; Su D; Hart T; Chen J
    Nucleic Acids Res; 2021 Aug; 49(14):8214-8231. PubMed ID: 34320214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.
    Southgate HED; Chen L; Tweddle DA; Curtin NJ
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32354033
    [No Abstract]   [Full Text] [Related]  

  • 9. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
    Wengner AM; Siemeister G; Lücking U; Lefranc J; Wortmann L; Lienau P; Bader B; Bömer U; Moosmayer D; Eberspächer U; Golfier S; Schatz CA; Baumgart SJ; Haendler B; Lejeune P; Schlicker A; von Nussbaum F; Brands M; Ziegelbauer K; Mumberg D
    Mol Cancer Ther; 2020 Jan; 19(1):26-38. PubMed ID: 31582533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
    Shi C; Qin K; Lin A; Jiang A; Cheng Q; Liu Z; Zhang J; Luo P
    J Exp Clin Cancer Res; 2022 Sep; 41(1):268. PubMed ID: 36071479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.
    Takeuchi M; Tanikawa M; Nagasaka K; Oda K; Kawata Y; Oki S; Agapiti C; Sone K; Miyagawa Y; Hiraike H; Wada-Hiraike O; Kuramoto H; Ayabe T; Osuga Y; Fujii T
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805725
    [No Abstract]   [Full Text] [Related]  

  • 12. Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape.
    Qiu Y; Hu X; Zeng X; Wang H
    Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(11):1569-1576. PubMed ID: 36305726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the ATR-CHK1 Axis in Cancer Therapy.
    Rundle S; Bradbury A; Drew Y; Curtin NJ
    Cancers (Basel); 2017 Apr; 9(5):. PubMed ID: 28448462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
    Gachechiladze M; Skarda J; Bouchalova K; Soltermann A; Joerger M
    Front Oncol; 2020; 10():581217. PubMed ID: 33224881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the DNA Damage Response Machinery for Lung Cancer Treatment.
    Venugopala KN
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
    Hunia J; Gawalski K; Szredzka A; Suskiewicz MJ; Nowis D
    Front Mol Biosci; 2022; 9():1073797. PubMed ID: 36533080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Effect of a Mesothelin-Targeted
    Wickstroem K; Hagemann UB; Cruciani V; Wengner AM; Kristian A; Ellingsen C; Siemeister G; Bjerke RM; Karlsson J; Ryan OB; Linden L; Mumberg D; Ziegelbauer K; Cuthbertson AS
    J Nucl Med; 2019 Sep; 60(9):1293-1300. PubMed ID: 30850485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
    Lamberti G; Andrini E; Sisi M; Federico AD; Ricciuti B
    Future Oncol; 2020 Aug; 16(23):1751-1766. PubMed ID: 32539551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the DNA damage response in oncology: past, present and future perspectives.
    Basu B; Yap TA; Molife LR; de Bono JS
    Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of the ATM-Chk2 DNA damage response through the base excision repair pathway.
    Chou WC; Hu LY; Hsiung CN; Shen CY
    Carcinogenesis; 2015 Aug; 36(8):832-40. PubMed ID: 26025911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.